Lapatinib

Type: Keyphrase
Name: Lapatinib
First reported 8 hours ago - Updated 8 hours ago - 1 reports

Clinical Trials and Studies: ALTTO test of dual HER2 blockade finds single agent remains the gold standard

By a News Reporter-Staff News Editor at Women's Health Weekly -- In the largest clinical trial testing the effectiveness of one versus two drugs to treat HER2-positive breast cancer, lapatinib (Tykerb) did not add benefit to the standard trastuzumab (Herceptin) ... [Published NewsRX - 8 hours ago]
First reported Jul 25 2014 - Updated Jul 25 2014 - 1 reports

Drugs to Avoid in Patients on Tyrosine Kinase Inhibitors

With the rapid and widespread uptake of tyrosine kinase inhibitors (TKIs) in oncology over the past several years, serious drug–drug interactions are an "increasing risk," according a new report.To guarantee the safe use of TKIs, "a drugs review for each ... [Published Diabetes Care - Jul 25 2014]
First reported Jul 23 2014 - Updated Jul 23 2014 - 1 reports

Neratinib Comes Through For Puma

Yet another entry in the "Why do people keep investing in biopharma?" files. Take a look at the case of Puma Biotechnology. Their stock was as high as $140/share earlier in the year, and it gradually deflated to the high 50s/low 60s as time went on. ... [Published In the Pipeline - Jul 23 2014]
First reported Jul 19 2014 - Updated Jul 19 2014 - 1 reports

Dr. Tripathy on Decision-Making for Sequencing Therapies for HER2-Positive MBC

[embedded content] Debu Tripathy, MD, co-leader, Women's Cancer Program, University of Southern California Norris Comprehensive Cancer Center, discusses a decision-making framework for sequencing therapies for HER2-positive metastatic breast cancer.While ... [Published OncLive - Jul 19 2014]
First reported Jul 17 2014 - Updated Jul 17 2014 - 1 reports

Keeping the heart in breast cancer treatment

Breast cancer awareness campaigns stress the importance of "saving the breasts" - but what about saving the heart?Breast cancer patients who are positive for the HER2 gene may be at increased risk for heart damage during chemotherapy, according to a new ... [Published Ecancer Medicalscience - Jul 17 2014]
First reported Jul 17 2014 - Updated Jul 17 2014 - 1 reports

Management of Breast Cancer Brain Metastases Is Moving Forward, but New Options Are Still Needed

Breast cancer brain metastases (BCBMs) are challenging, as they can occur up to several years after diagnosis and in the setting of controlled extracranial disease. Increased survival of breast cancer patients through more effective systemic treatments ... [Published Cancernetwork.com - Jul 17 2014]
First reported Jul 16 2014 - Updated Jul 17 2014 - 2 reports

Trastuzumab emtansine superior to physicians’ preferred treatments in pre-treated advanced HER2 positive breast cancer

by ecancer reporter Clare SansomAbout 15-20% of patients diagnosed with invasive breast cancer have tumours in which the gene human epidermal growth factor receptor 2 (HER2) is over-expressed.Patients with these HER2 positive breast cancers have a poor ... [Published Ecancer Medicalscience - Jul 16 2014]
First reported Jul 14 2014 - Updated Jul 15 2014 - 1 reports

T-DM1 Poised to Set New Standard in HER2-Positive Metastatic Breast Cancer

Adam Brufsky, MD, PhDThe antibody-drug conjugate T-DM1 (ado-trastuzumab emtansine; Kadcyla) will have an impact on the entire spectrum of care for patients with metastatic HER2-positive breast cancer, resulting in a greater emphasis on patient selection ... [Published OncLive - Jul 14 2014]
First reported Jul 11 2014 - Updated Jul 11 2014 - 1 reports

T-DM1 Storms All Stages of HER2+ Breast Cancer

Trastuzumab Emtansine Versus Treatment of Physician's Choice for Pretreated HER2-Positive Advanced Breast Cancer (TH3RESA): A Randomised, Open-label, Phase 3 TrialKrop IE, Kim SB, González-Martín E, et al; TH3RESA Study CollaboratorsLancet Oncol. 201 ... [Published General Medicine eJournal - Jul 11 2014]
First reported Jul 09 2014 - Updated Jul 10 2014 - 2 reports

Ado-Trastuzumab Emtansine as a Late Treatment for HER2-Positive Metastatic Breast Cancer—Better and Less Toxic Than Physician’s Choice

TH3RESA confirms that, in addition to benefit in earlier-line treatment shown in the EMILIA trial, ado-trastuzumab emtansine is more effective and less toxic than other options in heavily pretreated patients who have had disease progression on multiple ... [Published The ASCO Post - Jul 10 2014]
First reported Jul 10 2014 - Updated Jul 10 2014 - 1 reports

Study Results from Fudan University Update Understanding of Breast Cancer (Lapatinib-incorporated lipoprotein-like nanoparticles: preparation and a...

Study Results from Fudan University Update Understanding of Breast Cancer (Lapatinib-incorporated lipoprotein-like nanoparticles: preparation and a proposed breast cancer-targeting mechanism)By a News Reporter-Staff News Editor at Cancer Weekly -- Investigators ... [Published HispanicBusiness.com - Jul 10 2014]
First reported Jul 03 2014 - Updated Jul 03 2014 - 1 reports

Impact of ALTTO Results on Patients With HER2-Positive Breast Cancer

, division of oncology at the Stanford University Medical Center, discusses the results of the ALTTO trial (Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation). Following surgery, the trial randomized patients with HER2-positive breast cancer ... [Published Cancernetwork.com - Jul 03 2014]

Quotes

...Therefore, if possible, the concomitant use of these TKIs with a proton-pump inhibitor, H₂ antagonist, or antacid "should be avoided, or the time of drug intake should be separated by several hours at least" the authors advise
...On a conference call to discuss the results, Sir Andrew said: "I remain very concerned about allegations concerning our China business. The situation is complicated and difficult and while the investigation is active, there is little I can add."
...echolamines), a decrease in protective growth factor (neuregulin), and an increase in blood pressure," says lead author Dr Carrie Geisberg Lenneman. "This may contribute to why certain patients have a decline in heart function during chemotherapy treatment."
...According to news reporting originating from Shanghai , People's Republic of China , by NewsRx correspondents, research stated, "Lapatinib is a dual inhibitor of EGFR and human epidermal growth factor receptor 2 (HER2), and used to treat advanced breast cancer. To overcome its poor water solubility, we constructed lapatinib-incorporated lipoprotein-like nanoparticles (LTNPs), and evaluated the particle characteristics and possible anti-breast cancer mechanisms."

More Content

All (62) | News (58) | Reports (0) | Blogs (4) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Clinical Trials and Studies: ALTTO test of dual... [Published NewsRX - 8 hours ago]
Drugs to Avoid in Patients on Tyrosine Kinase I... [Published Diabetes Care - Jul 25 2014]
GlaxoSmithKline slashes forecast as 2nd-qtr sal... [Published Pharma Letter - Jul 24 2014]
Examining the Protective Role of ErbB2 Modulati... [Published Toxicological Sciences - Jul 24 2014]
Neratinib Comes Through For Puma [Published In the Pipeline - Jul 23 2014]
Dr. Tripathy on Decision-Making for Sequencing ... [Published OncLive - Jul 19 2014]
Clinical Study: Sympathetic nervous system alte... [Published Ecancer Medicalscience - Jul 18 2014]
Keeping the heart in breast cancer treatment [Published Ecancer Medicalscience - Jul 17 2014]
Management of Breast Cancer Brain Metastases Is... [Published Cancernetwork.com - Jul 17 2014]
Approaches for Optimal Drug Development and Cli... [Published Cancernetwork.com - Jul 17 2014]
Trastuzumab emtansine superior to physicians’ p... [Published Ecancer Medicalscience - Jul 16 2014]
Negative ALTTO Trial Shakes Up Breast Ca Research [Published Pharmacy Practice News - Jul 16 2014]
T-DM1 Poised to Set New Standard in HER2-Positi... [Published OncLive - Jul 14 2014]
T-DM1 Storms All Stages of HER2+ Breast Cancer [Published General Medicine eJournal - Jul 11 2014]
ASCO Guideline for Management of Brain Metastas... [Published The ASCO Post - Jul 10 2014]
Ado-Trastuzumab Emtansine as a Late Treatment f... [Published The ASCO Post - Jul 10 2014]
Study Results from Fudan University Update Unde... [Published HispanicBusiness.com - Jul 10 2014]
ASCO Clinical Practice Guideline: Disease Manag... [Published The ASCO Post - Jul 09 2014]
Ado-Trastuzumab Emtansine Improves Progression-... [Published The ASCO Post - Jul 09 2014]
How Do We Treat Patients with Gastric Cancer? [Published Oncology Times - Jul 09 2014]
Past, Present, and Future Challenges in Breast ... [Published Journal of Clinical Oncology - Jul 04 2014]
Impact of ALTTO Results on Patients With HER2-P... [Published Cancernetwork.com - Jul 03 2014]
Findings from University Hospital Update Knowle... [Published Pharmacy Choice - Jun 30 2014]
BPA Stimulates Growth of Breast Cancer Cells [Published MedIndia - Jun 28 2014]
Endocrine disruptors: New studies confirm dange... [Published Sott.net - Jun 28 2014]
T-DM1 Now Preferred for Progressive HER2 Breast... [Published Diabetes Care - Jun 27 2014]
Analysing the impact on social networks: Twitte... [Published pharmaphorum - Jun 27 2014]
10 ASCO Takeaways for Primary Care Physicians [Published American Journal of Public Health - Jun 26 2014]
Tragic Carol Parkinson's cancer treatment fight [Published Irish Mirror - Jun 26 2014]
Patent Issued for Imaging Probes, Methods of Ma... [Published HispanicBusiness.com - Jun 26 2014]
1 2 3
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Neratinib Comes Through For Puma [Published In the Pipeline - Jul 23 2014]
Yet another entry in the "Why do people keep investing in biopharma?" files. Take a look at the case of Puma Biotechnology. Their stock was as high as $140/share earlier in the year, and it gradually deflated to the high 50s/low 60s as time went on. ...
GSK's Phase III trial of breast cancer combinat... [Published PBR - News - Jun 02 2014]
UK-based drug maker GlaxoSmithKline (GSK) has reported results from its Phase III trial of two anti-HER2 agents, lapatinib (Tykerb/Tyverb) and trastuzumab, as an adjuvant treatment for patients with HER2 positive primary breast cancer. ...
Cost Control in the UK [Published Balloon Juice - Apr 23 2014]
Via the Guardian: A Herceptin-style drug that can offer some women with advanced breast cancer nearly six months of extra life has been turned down for use in the NHS because of its high cost. In draft guidance now open to consultation, the ...
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - Apr 01 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.